ubiquinol-cytochrome c reductase hinge protein pseudogene 4Genealiases: []
Q-omics provides the consensus-scored UQCRHP4 profile across patient tissues and cancer cell-line models. UQCRHP4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UQCRHP4 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, UQCRHP4 RNA expression shows 9,259 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LIHC, THCA, and SARC as cancer lineages where UQCRHP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRHP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRHP4 survival associations across molecular data types. UQCRHP4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRHP4 RNA expression–survival associations across cancer types. High UQCRHP4 expression shows unfavorable associations in LIHC, READ, UVM, UCEC, THCA and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UQCRHP4 RNA expression.
This table summarizes UQCRHP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for UQCRHP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRHP4 shows lower tumor expression in THCA and BLCA and higher tumor expression in LUAD. The THCA box plot shows higher UQCRHP4 RNA expression in normal versus tumor tissue (log2 FC = −0.370, t-test p < 0.001).
This table shows molecular features associated with UQCRHP4 in patient tissues and cancer cell lines. In patient samples, UQCRHP4 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
